<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00472381</url>
  </required_header>
  <id_info>
    <org_study_id>P060202</org_study_id>
    <nct_id>NCT00472381</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Continuous Intravenous Versus Usual Subcutaneous Insulin in Acute Ischemic Stroke</brief_title>
  <acronym>INSULINFARCT</acronym>
  <official_title>Assessment of Continuous Intravenous Insulin Protocol Versus Subcutaneous Insulin in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperglycaemia is a frequent finding in acute ischemic stroke and associated with poor
      outcome. But the modalities of glucose lowering are still debated. This study will test the
      efficacy and safety of continuous intravenous insulin protocol versus usual subcutaneous
      insulin in acute ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is demonstrated that post-stroke hyperglycaemia is associated with poor outcome. Yet, the
      efficiency of aggressive insulin serum glucose control is not established. Furthermore the
      modalities of insulin administration are discussed since US and European guidelines recommend
      subcutaneous administration, whereas some groups use intravenous administration of insulin.
      The purpose of this study is to compare the efficacy and the safety of a continuous
      intravenous insulin protocol versus classical subcutaneous administration of insulin. The
      study will include carotid territory stroke at the acute stage (&lt; 6 hours of onset) confirmed
      by MRI, and randomized in intravenous versus subcutaneous insulin. The percentage of patients
      in the target range (mean capillary glycaemia within 24 hours &lt; 7 mmol/l) is the primary
      outcome. The secondary outcomes include comparison of Modified Rankin Scale at 3 months, rate
      of hypoglycaemic events and comparison of Infarct Growth as measured on MRI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients in the glucose target range within 24 hours of the initiation of treatment.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale at three months</measure>
    <time_frame>three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic resonance imaging (MRI) infarct growth at one day</measure>
    <time_frame>one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with hypoglycaemic event (&lt; 3 mmol/l)</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Acute Stroke</condition>
  <condition>Acute Cerebral Ischemia</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  Carotid territory stroke

          -  MRI performed in the first five hours of stroke onset

          -  Baseline National Institutes of Health Stroke Scale (NIHSS) &gt; 4 or &lt; 26

          -  Time between MRI and treatment under one hour

        Exclusion Criteria:

          -  Pre-existing Modified Rankin Scale of three or higher

          -  Advanced or terminal illness with risk of death in the next 6 months, addiction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Samson, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AP-HP Urgences cerebro vasculaires La Pitié Salpétrière</name>
      <address>
        <city>Poissy</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://stroke.ahajournals.org</url>
    <description>DOI:10.1161/STROKEAHA.112.657122</description>
  </link>
  <results_reference>
    <citation>Samson Y, Bruandet M, Lejeune M, Deltour S, Grimaldi A. [Insulin in the treatment of ischemic stroke]. Presse Med. 2006 Apr;35(4 Pt 2):696-8. Review. French.</citation>
    <PMID>16614616</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2007</study_first_submitted>
  <study_first_submitted_qc>May 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2007</study_first_posted>
  <last_update_submitted>June 4, 2014</last_update_submitted>
  <last_update_submitted_qc>June 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Ischemic Stroke</keyword>
  <keyword>Post-Stroke Hyperglycaemia</keyword>
  <keyword>Insulin treatment</keyword>
  <keyword>Insulin</keyword>
  <keyword>DWI</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

